2 results
Approved WMORecruiting
Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or persistent disease and Cohort 2 - LN-145 monotherapy in patients previously treated with an antiprogrammedcell death…
Approved WMOCompleted
The first main objective is to investigate the pharmacokinetic properties of dry powder amikacin at different dosages and compare the peak serum values to a single i.v. dose. The secondary main objective is to assess the local tolerability of dry…